Meeting
2012 ASCO Annual Meeting
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study.
Authors
Michael Ewer
University of Texas M. D. Anderson Cancer Center, Houston, TX
Michael Ewer , José Baselga , Emma Clark , Mark Benyunes , Graham Ross , Sandra M. Swain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT00567190
Citation
J Clin Oncol 30, 2012 (suppl; abstr 533^)
Abstract #
533^
Poster Bd #
23
Abstract Disclosures
Similar Posters
First Author: Nicholas Patrick McAndrew
Poster
2019 ASCO Annual Meeting
End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).
First Author: Sandra M. Swain
Poster
2015 ASCO Annual Meeting
Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel.
First Author: David Miles
Poster
2023 ASCO Breakthrough
Retrospective observational study of outcomes in HER2-positive metastatic breast cancer patients treated with trastuzumab emtansine in single center.
First Author: WanChen Hsieh